Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Gracell Biotechnologies Inc. GRCL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CN • USD

SharesGrow Score
26/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$6.00
-41.5%

GRCL Insider Ownership

Top Holder
-
Buys (12 mo)
0
$0.00 value
Sells (12 mo)
0
$0.00 value

No ownership data available for GRCL.

People Also View

BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message